Celldex price target raised to $50 from $46 by Morgan Stanley
Morgan Stanley raised its price target on Celldex Therapeutics to $50.00 per share from $46.00. The stock is maintained at Overweight by Morgan Stanley, per Benzinga via TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.